IceCure Medical has been granted a new patent in China for a connector used in its cryogenic tumor treatment technology, expanding its intellectual property portfolio to 42 patents worldwide. This patent strengthens IceCure's protection of its proprietary cryoablation technology in key international markets, following recent regulatory approval to market its ProSense system in China. The company focuses on minimally invasive tumor destruction using freezing technology, primarily for breast, kidney, bone, and lung cancers. This move supports IceCure's long-term strategy to protect and grow its innovative medical technology globally.
IceCure Medical's new patent in China for its cryogenic system connector provides context for health-sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: out of 150 priced US health-sector stocks, 121 rose and 18 fell. Notable movers include Inovio Pharmaceuticals Inc (INO) at USD 1.32 with a +8.64% change and a typical hold time of 41 days, Cassava Sciences Inc (FLNA) at USD 0.48 with a +5.94% change, and LifeStance Health Group Inc. (LFST) at USD 12.99 with a -5.66% change. The most notable figure is the 121 stocks that rose today.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
